| 101 |
22846973 | Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. | 2012 |
1 |
| 102 |
22941289 | The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. | 2012 Oct |
2 |
| 103 |
22962324 | Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. | 2012 Nov |
2 |
| 104 |
23099651 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. | 2012 Dec |
1 |
| 105 |
23227538 | [Advances in the study of structural modifications of multi-target anticancer drug sorafenib]. | 2012 Sep |
1 |
| 106 |
23231599 | Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. | 2012 Dec 11 |
1 |
| 107 |
20443129 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. | 2011 Jan |
1 |
| 108 |
20552299 | Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. | 2011 Dec |
1 |
| 109 |
20803231 | The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. | 2011 Mar |
2 |
| 110 |
20821331 | Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. | 2011 Jul |
1 |
| 111 |
20926530 | Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. | 2011 Jan |
1 |
| 112 |
20944654 | The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. | 2011 Feb |
1 |
| 113 |
21079155 | Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. | 2011 Jan 20 |
2 |
| 114 |
21098323 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. | 2011 Jan 1 |
1 |
| 115 |
21192261 | RAF inhibition and induction of cutaneous squamous cell carcinoma. | 2011 Mar |
2 |
| 116 |
21224376 | Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. | 2011 Mar 1 |
1 |
| 117 |
21289252 | Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. | 2011 Apr |
2 |
| 118 |
21487053 | Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | 2011 Jun |
1 |
| 119 |
21529991 | Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. | 2011 Nov |
1 |
| 120 |
21531053 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. | 2011 Jul |
2 |
| 121 |
21689083 | Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. | 2011 Feb |
3 |
| 122 |
21734462 | c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. | 2011 Sep 15 |
2 |
| 123 |
21816375 | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. | 2011 Aug |
1 |
| 124 |
21905615 | [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition]. | 2011 |
1 |
| 125 |
22174910 | Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. | 2011 |
2 |
| 126 |
22179180 | Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. | 2011 Dec |
3 |
| 127 |
19554262 | Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. | 2010 Oct |
1 |
| 128 |
19890601 | Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. | 2010 Jul |
1 |
| 129 |
19935717 | Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. | 2010 Feb 25 |
3 |
| 130 |
20078249 | Toxicity of sorafenib: clinical and molecular aspects. | 2010 Mar |
1 |
| 131 |
20149262 | Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. | 2010 Feb 12 |
2 |
| 132 |
20149658 | Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. | 2010 Mar 1 |
1 |
| 133 |
20197396 | Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. | 2010 Mar |
2 |
| 134 |
20301194 | Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. | 2010 Jul |
2 |
| 135 |
20432459 | Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. | 2010 Aug |
1 |
| 136 |
20698202 | Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. | 2010 May-Jun |
1 |
| 137 |
20810616 | Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. | 2010 Nov |
2 |
| 138 |
20812347 | Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. | 2010 Dec 1 |
2 |
| 139 |
20944096 | Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. | 2010 Sep |
1 |
| 140 |
21102438 | AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. | 2010 Dec |
1 |
| 141 |
21187475 | PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. | 2010 Dec |
4 |
| 142 |
21351273 | Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. | 2010 Dec 15 |
2 |
| 143 |
24367212 | Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. | 2010 Nov 2 |
1 |
| 144 |
19255327 | Phase II trial of sorafenib in metastatic thyroid cancer. | 2009 Apr 1 |
2 |
| 145 |
19296866 | Protein kinase inhibitors: contributions from structure to clinical compounds. | 2009 Feb |
1 |
| 146 |
19436197 | Sorafenib tosylate in advanced kidney cancer: past, present and future. | 2009 Jul |
1 |
| 147 |
19633425 | Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. | 2009 Sep |
4 |
| 148 |
19652055 | Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. | 2009 Sep 10 |
1 |
| 149 |
19660024 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. | 2009 Nov |
1 |
| 150 |
19667065 | Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation. | 2009 Oct 9 |
2 |